Literature DB >> 12490431

Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas.

Mauricio R Loureiro-Silva1, Gregory W Cadelina, Roberto J Groszmann.   

Abstract

Intrahepatic nitric oxide (NO) production is decreased in cirrhotic livers. Our objective was to identify, in cirrhotic rat livers, intrahepatic vascular segments where the deficit of NO facilitates the effect of vasoconstrictors. By using a modified rat liver perfusion system with measurement of both the perfusion and sinusoidal (wedged hepatic vein) pressures, we studied the effect of the NO synthase blocker N(omega)-nitro-l-arginine (l-NNA) on the response to methoxamine (alpha(1)-adrenoreceptor agonist) in different segments of the intrahepatic circulation of normal and cirrhotic rat livers. l-NNA enhanced the presinusoidal, sinusoidal, and postsinusoidal responses to methoxamine in normal livers as well as the presinusoidal response in cirrhotic livers. However, l-NNA did not change the already enhanced sinusoidal/postsinusoidal response to methoxamine in cirrhotic livers. The postsinusoidal response to methoxamine was higher in cirrhotic rats with ascites than in those without ascites. We concluded that NO modulates the presinusoidal, sinusoidal, and postsinusoidal vascular tone in normal livers. NO production in cirrhotic rat livers is severely impaired in the sinusoidal and postsinusoidal areas but is preserved in the presinusoidal area, as evidenced by its normal response to l-NNA. We speculate that an increased postsinusoidal response to catecholamines may participate in the genesis of ascites in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490431     DOI: 10.1152/ajpgi.00452.2002

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  13 in total

1.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

Review 2.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

3.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 4.  Pathophysiology and Management of Variceal Bleeding.

Authors:  Saleh A Alqahtani; Sunguk Jang
Journal:  Drugs       Date:  2021-03-12       Impact factor: 9.546

Review 5.  The portal hypertension syndrome: etiology, classification, relevance, and animal models.

Authors:  Jaime Bosch; Yasuko Iwakiri
Journal:  Hepatol Int       Date:  2017-10-24       Impact factor: 6.047

Review 6.  Pathophysiology and management of pediatric ascites.

Authors:  Mahmoud Sabri; Miguel Saps; John M Peters
Journal:  Curr Gastroenterol Rep       Date:  2003-06

7.  Resident mesenchymal cells and fibrosis.

Authors:  Nicol Hutchison; Cécile Fligny; Jeremy S Duffield
Journal:  Biochim Biophys Acta       Date:  2012-12-04

8.  Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis.

Authors:  Tung-Ming Leung; George L Tipoe; Emily C Liong; Thomas Y H Lau; Man-Lung Fung; Amin A Nanji
Journal:  Int J Exp Pathol       Date:  2008-04-21       Impact factor: 1.925

9.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.

Authors:  Q Zhou; M Hennenberg; J Trebicka; K Jochem; L Leifeld; E Biecker; T Sauerbruch; J Heller
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

10.  Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

Authors:  Leonie Halverscheid; Peter Deibert; René Schmidt; Hubert E Blum; Torsten Dunkern; Benedikt H J Pannen; Wolfgang Kreisel
Journal:  BMC Gastroenterol       Date:  2009-09-18       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.